Analysis

Lexicon Pharmaceuticals, Inc. (LXRX) Stock Analysis

Lexicon Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to LXRX.

websiteLXRX/analysis/LXRX

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to LXRX.

Stock profile

Ticker

LXRX

Asset type

Stock

Market cap

$892.8M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Lexicon Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • LXRX primary listing
  • LX31

Latest Lexicon Pharmaceuticals, Inc. news

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design ...

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat a...

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat a...

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical de...

Research sections

Valuation

Review valuation context for Lexicon Pharmaceuticals, Inc..

Future growth

Review future growth context for Lexicon Pharmaceuticals, Inc..

Past performance

Review past performance context for Lexicon Pharmaceuticals, Inc..

Financial health

Review financial health context for Lexicon Pharmaceuticals, Inc..

Dividend

Review dividend context for Lexicon Pharmaceuticals, Inc..

Management

Review management context for Lexicon Pharmaceuticals, Inc..

Ownership

Review ownership context for Lexicon Pharmaceuticals, Inc..

Other information

Review other information context for Lexicon Pharmaceuticals, Inc..

Community

Review community context for Lexicon Pharmaceuticals, Inc..